Parkinson dementia: PET findings

Pet and Spect in Neurology

Volumn , Issue , 2014, Pages 359-372

  Bohnen, Nicolaas I ^a   Frey, Kirk A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940717986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-54307-4_16     Document Type: Chapter

References (78)

1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20:1255-1263
2. Albin RL, Minoshima S, D’Amato CJ et al (1996) Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47:462-466
3. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357-381
4. Alves G, Larsen JP, Emre M et al (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21:1123-1130
5. Ballard C, Ziabreva I, Perry R et al (2006) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67:1931-1934
6. Bjorklund A, Lindvall O (1984) Dopamine-containing systems in the CNS. In: Bjorklund A, Hokfelt T (eds) Handbook of chemical neuroanatomy. Elsevier, Amsterdam, pp 55-122
7. Bohnen NI, Albin RL (2011) White matter lesions in Parkinson disease. Nat Rev Neurol 7: 229-236
8. Bohnen NI, Minoshima S, Giordani B et al (1999) Motor correlates of occipital glucose hypome- tabolism in Parkinson’s disease without dementia. Neurology 52:541-546
9. Bohnen NI, Kaufer DI, Ivanco LS et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 60:1745-1748
10. Bohnen NI, Kaufer DI, Hendrickson R et al (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253:242-247
11. Bohnen NI, Muller ML, Koeppe RA et al (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:1670-1676
12. Bohnen NI, Koeppe RA, Minoshima S et al (2011) Cerebral glucose metabolic features of Parkinson disease and incident dementia: Longitudinal study. J Nucl Med 52:848-855
13. Bohnen NI, Mueller MLTM, Kotagal V et al (2012) Heterogeneity of cholinergic denervation in Parkinson disease. J Cereb Blood Flow Metab 32:1609-1617
14. Burack MA, Hartlein J, Flores HP et al (2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74:77-84
15. Burke JF, Albin RL, Koeppe RA et al (2011) Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 134:1647-1657
16. Churchyard A, Lees A (1997) The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson’s disease. Neurology 49:1570-1576
17. Compta Y, Parkkinen L, O’sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: Which is more important? Brain 134:1493-1505
18. 11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331-1338
19. Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2:229-237
20. Foster ER, Campbell MC, Burack MA et al (2010) Amyloid imaging of Lewy body-associated disorders. Mov Disord 25:2516-2523
21. Frey KA, Koeppe RA, Kilbourn MR et al (1996) Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol 40:873-884
22. Frost JJ, Rosier AJ, Reich SG et al (1993) Positron emission tomographic imaging of the dopamine transporter with1 1C-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol 34:423-431
23. Gagnon JF, Postuma RB, Mazza S et al (2006) Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5:424-432
24. Garnett ES, Firnau G, Chan PKH et al (1978) [18 F] fluoro-dopa, an analogue of dopa, and its use in direct measurement of storage, degeneration, and turnover of intracerebral dopamine. Proc Natl Acad Sci U S A 75:464-467
25. Gibb W (1989) Dementia and Parkinson’s disease. Br J Psychiatry 154:596-614
26. Gilman S, Koeppe RA, Nan B et al (2010) Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74:1416-1423
27. Goldman-Rakic PS (1998) The cortical dopamine system: Role in memory and cognition. Adv Pharmacol 42:707-711
28. Gomperts SN, Rentz DM, Moran E et al (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71:903-910
29. Heckers S, Geula C, Mesulam M (1992) Cholinergic innervation of the human thalamus: Dual origin and differential nuclear distribution. J Comp Neurol 325:68-82
30. Hely MA, Reid WG, Adena MA et al (2008) The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov Disord 23:837-844
31. Hilker R, Thomas AV, Klein JC et al (2005) Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 65:1716-1722
32. Hirsch EC, Graybiel AM, Duyckaerts C et al (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 84:5976-5980
33. Holthoff VA, Vieregge P, Kessler J et al (1994) Discordant twins with Parkinson’s disease: Positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 36:176-182
34. Hu XS, Okamura N, Arai H et al (2000) 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 55:1575-1577
35. Huang C, Tang C, Feigin A et al (2007) Changes in network activity with the progression of Parkinson’s disease. Brain 130:1834-1846 Irvine GB, El-Agnaf OM, Shankar GM et al (2008) Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med 14:451-464
36. Ito K, Nagano-Saito A, Kato T et al (2002) Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: A 6-[18 F] fluoro-L-dopa PET study. Brain 125:1358-1365
37. Jellinger KA (2000) Morphological substrates of mental dysfunction in Lewy body disease: An update. J Neural Transm 59(Suppl):185-212
38. Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson’s disease.42— J Neurol Sci 248:167-172
39. Johansson A, Savitcheva I, Forsberg A et al (2008) [(11) C] - PIB imaging in patients with Parkinson’s disease: Preliminary results. Parkinsonism Relat Disord 14:345-347
40. Kalaitzakis ME, Graeber MB, Gentleman SM et al (2008) Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 67:155-161
41. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200-1213
42. Klein JC, Eggers C, Kalbe E et al (2010) Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74(11):885-892
43. Koeppe RA, Gilman S, Joshi A et al (2005)11C-DTBZ and18F-FDG PET measures in differentiating dementias. J Nucl Med 46:936-944
44. Kotagal V, Albin RL, Muller MLTM et al (2012) Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 71(4):560-568
45. Kovari E, Gold G, Herrmann FR et al (2003) Lewy body densities in the entorhinal and anterior cingu- late cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berlin) 106:83-88
46. Lee MS, Rinne JO, Marsden CD (2000) The pedunculopontine nucleus: Its role in the genesis of movement disorders. Yonsei Med J 41:167-184
47. Luis CA, Barker WW, Gajaraj K et al (1999) Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 14:526-533
48. Maetzler W, Reimold M, Liepelt I et al (2008) [(11) C] PIB binding in Parkinson’s disease dementia. Neuroimage 39:1027-1033
49. Maetzler W, Liepelt I, Reimold M et al (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34:107-112
50. Mahler ME, Cummings JL (1990) Alzheimer disease and the dementia of Parkinson disease: Comparative investigations. Alzheimer Dis Assoc Disord 4:133-149
51. Marder K (2010) Cognitive impairment and dementia in Parkinson’s disease. Mov Disord 25 (Suppl 1):S110-S116
52. Marion MH, Qurashi M, Marshall G et al (2008) Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson’s disease? J Neurol 255:192-196
53. Mattis PJ, Tang CC, Ma Y et al (2011) Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 77:858-865
54. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guideline for the clinical and pathological diagnosis of dementia with Lewy bodies (LBD): Report of the Consortium on DLB International Workshop. Neurology 47:1113-1124
55. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1863-1872
56. Mesulam M (2004) The cholinergic lesion of Alzheimer’s disease: Pivotal factor or side show? Learn Mem 11:43-49
57. Mesulam MM, Geula C (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 275:216-240
58. Minoshima S, Foster NL, Kuhl DE (1994) Posterior cingulate cortex in Alzheimer’s disease. Lancet 344:895
59. Minoshima S, Foster NL, Sima AA et al (2001) Alzheimer’s disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50:358-365
60. Nagano-Saito A, Kato T, Arahata Y et al (2004) Cognitive- and motor-related regions in Parkinson’s disease: Fdopa and FDG PET studies. Neuroimage 22:553-561
61. Perry EK, Curtis M, Dick DJ et al (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48:413-421
62. Petrou M, Bohnen NI, Muller MLTM et al (2012) Ap-amyloid deposition and cognition in Parkinson disease patients at risk for development of dementia. Neurology 79(11):1161-1167
63. Polito C, Berti V, Ramat S et al (2012) Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging 33(206):e29-e39
64. Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia.78— Neurology 68:1718-1725
65. Ruberg M, Rieger F, Villageois A et al (1986) Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease. Brain Res 362:83-91
66. Shimada H, Hirano S, Shinotoh H et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273-278
67. Shinotoh H, Namba H, Yamaguchi M et al (1999) Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol 46:62-69
68. Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055-1061
69. Song IU, Kim YD, Cho HJ et al (2013) An FP-CIT PET Comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord 27(1):51-55
70. Taylor JP, Rowan EN, Lett D et al (2008) Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 79:1318-1323
71. Tsigelny IF, Crews L, Desplats P et al (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS One 3:e3135
72. Vander Borght T, Minoshima S, Giordani B et al (1997) Cerebral metabolic differences in Parkinson’s and Alzheimer’s disease matched for dementia severity. J Nucl Med 38:797-802
73. Villemagne VL, Okamura N, Pejoska S et al (2011) In vivo assessment of vesicular monoamine transporter type 2 in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 68:905-912
74. Villemagne VL, Okamura N, Pejoska S et al (2012) Differential diagnosis in Alzheimer’s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neurodegener Dis 10(1-4):161-165
75. Williams-Gray CH, Hampshire A, Barker RA et al (2008) Attentional control in Parkinson’s disease is dependent on COMT val 158 met genotype. Brain 131:397-408
76. Williams-Gray CH, Evans JR, Goris A et al (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958-2969
77. Womack KB, Diaz-Arrastia R, Aizenstein HJ et al (2011) Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol 68:329-337
78. Zweig RM, Jankel WR, Hedreen JC et al (1989) The pedunculopontine nucleus in Parkinson’s disease. Ann Neurol 26:41-46